Passage Bio Q3 2026 Earnings Results & Report

Passage Bio EPS Results

• Actual EPS: -$1.47
• Consensus EPS: -$2.43
• Beat/Miss: Beat by +$0.96
• One Year Ago EPS: N/A
• EPS Beat Rate: 5 of last 8 quarters

Passage Bio Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Passage Bio (NASDAQ:PASG) is a clinical-stage biotechnology company focused on developing gene therapies for diseases of the central nervous system. The company uses adeno-associated virus (AAV) delivery technologies to develop treatments intended to address the underlying genetic causes of severe neurological and neurodegenerative disorders.

Its research programs have included PBGM01, an investigational gene therapy for GM1 gangliosidosis, a rare inherited disorder caused by mutations affecting the GLB1 gene. Passage Bio has also advanced programs for other conditions, including Krabbe disease and frontotemporal dementia. These therapies remain investigational and have not been approved for commercial use.

Passage Bio was founded in 2018 and is based in Philadelphia, Pennsylvania. The company was established with connections to the University of Pennsylvania’s Gene Therapy Program and has conducted development activities through clinical and research collaborations. Passage Bio’s programs are intended for patients in markets where the company can obtain regulatory authorization and establish clinical or commercial access.

The company is led by William Chou, who has served as chief executive officer. As a development-stage biotechnology company, Passage Bio’s operations are primarily focused on research, clinical development, regulatory activities and collaboration rather than the sale of marketed products.